Pacira Biosciences Inc (NASDAQ:PCRX) insider Richard Scranton sold 9,040 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $43.10, for a total value of $389,624.00. Following the sale, the insider now directly owns 18,027 shares in the company, valued at approximately $776,963.70. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Richard Scranton also recently made the following trade(s):
- On Monday, June 3rd, Richard Scranton sold 15,510 shares of Pacira Biosciences stock. The stock was sold at an average price of $43.21, for a total value of $670,187.10.
Pacira Biosciences stock traded down $0.94 during trading on Monday, hitting $42.55. The company’s stock had a trading volume of 458,768 shares, compared to its average volume of 592,434. The stock has a market capitalization of $1.80 billion, a PE ratio of 146.72, a price-to-earnings-growth ratio of 2.45 and a beta of 1.14. The stock has a fifty day moving average price of $44.00. Pacira Biosciences Inc has a 1-year low of $31.51 and a 1-year high of $55.00. The company has a debt-to-equity ratio of 0.99, a current ratio of 8.62 and a quick ratio of 7.83.
Large investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Pacira Biosciences by 22.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,950 shares of the company’s stock valued at $127,000 after buying an additional 538 shares during the period. Rhumbline Advisers raised its position in shares of Pacira Biosciences by 46.2% during the 4th quarter. Rhumbline Advisers now owns 54,649 shares of the company’s stock worth $2,351,000 after acquiring an additional 17,258 shares in the last quarter. Tygh Capital Management Inc. acquired a new stake in shares of Pacira Biosciences during the 4th quarter worth about $3,807,000. Smith Asset Management Group LP acquired a new stake in shares of Pacira Biosciences during the 4th quarter worth about $1,759,000. Finally, First Trust Advisors LP acquired a new stake in shares of Pacira Biosciences during the 4th quarter worth about $3,469,000. Institutional investors own 99.13% of the company’s stock.
Several research analysts have commented on the company. Wedbush set a $85.00 price target on Pacira Biosciences and gave the stock a “buy” rating in a research report on Friday. Stifel Nicolaus reissued a “sell” rating and issued a $33.00 target price on shares of Pacira Biosciences in a report on Friday, March 8th. Mizuho raised Pacira Biosciences from an “underperform” rating to a “neutral” rating and boosted their target price for the company from $29.00 to $38.00 in a report on Monday, May 6th. Zacks Investment Research raised Pacira Biosciences from a “hold” rating to a “buy” rating and set a $47.00 target price on the stock in a report on Friday, May 31st. Finally, Piper Jaffray Companies set a $55.00 target price on Pacira Biosciences and gave the company a “buy” rating in a report on Tuesday, April 9th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $54.53.
Pacira Biosciences Company Profile
Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.
Featured Story: P/E Growth (PEG)
Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.